Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Stepped Care for Depression and Musculoskeletal Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00118430
Recruitment Status : Completed
First Posted : July 11, 2005
Results First Posted : May 9, 2017
Last Update Posted : May 9, 2017
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Indiana University

Tracking Information
First Submitted Date  ICMJE July 6, 2005
First Posted Date  ICMJE July 11, 2005
Results First Submitted Date  ICMJE May 23, 2016
Results First Posted Date  ICMJE May 9, 2017
Last Update Posted Date May 9, 2017
Study Start Date  ICMJE September 2004
Actual Primary Completion Date July 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 28, 2017)
  • Brief Pain Inventory Interference [ Time Frame: Measured at Year 1 ]
    The BPI interference scale consists of 7 items, each scored from 0 (no interference) to 10 (complete interference), and the total score is the average of the 7 individual item scores. Therefore, the BPI interference score can range from 0 (lowest pain) to 10 (worst or highest pain).
  • HSCL-20 Depression Severity [ Time Frame: Measured at Year 1 ]
    This scale consists of 20 items, each scored from 0 (lowest) to 4 (highest or worst). The scale score is the average of the 20 items. Therefore, the HSCL-20 depression severity score can range from 0 (no depression) to 4 (highest or worst depression)
Original Primary Outcome Measures  ICMJE
 (submitted: July 6, 2005)
  • Pain
  • depressive symptoms
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 28, 2017)
  • Graded Chronic Pain Scale Disability Score [ Time Frame: Measured at Year 1 ]
    This scale ranges from 0 (no pain-specific disability) to 100 (highest or worst pain-specific disability)
  • Primary Care Visits [ Time Frame: Measured at Year 1 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: July 6, 2005)
  • Quality of life
  • health care usage and cost
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Stepped Care for Depression and Musculoskeletal Pain
Official Title  ICMJE Stepped Care for Affective Disorders and Musculoskeletal Pain
Brief Summary This study will evaluate the effectiveness of a stepped care approach in treating depression and reducing pain.
Detailed Description

In the United States, pain accounts for nearly 20% of all primary health care visits. In the majority of cases, the pain is musculoskeletal and primarily affects the lower back, hips, and knees. Studies have shown that at least one-third of patients with pain also suffer from depression. It has not been determined whether treatments for depression are effective in patients with comorbid pain and depression. The "Stepped Care for Affective Disorders and Musculoskeletal Pain" (SCAMP) study will determine the most effective treatment for patients with pain and depression.

This study will last 12 months and will comprise depressed and nondepressed participants. Nondepressed participants will receive no treatment. Depressed patients will be randomly assigned to receive standard of care or stepped care for 12 weeks. Standard of care may include cognitive therapy, antidepressant treatment, or other treatments. The stepped care group will receive 12 weeks of antidepressant treatment. Participants who respond to antidepressant treatment will continue their treatment for the duration of the study. Participants who do not respond to the treatment after 12 weeks will receive 6 weekly pain self-management sessions. During these sessions, an educator will teach participants how to manage their pain through exercise and relaxation techniques. Self-report scales and questionnaires will be used to assess participants' pain, depressive symptoms, health care usage and costs, and quality of life. Depressed participants will undergo assessments at study start and at Months 1, 3, 6, and 12. Nondepressed participants will undergo assessments at study start and at Months 3 and 12.

Study hypotheses: 1) Stepped care is more effective than usual care in improving depression and pain. 2) Stepped care is more effective than usual care in improving health-related quality of life, negative pain beliefs and behaviors, reduced opiate use, and health care costs. 3) Patients with musculoskeletal pain who are not depressed at baseline will have an incidence of depression less than 20% over 12 months of follow-up, characteristics that can be identified as risk factors for incident depression, baseline characteristics distinguishing them from depressed patients, and better pain and health status outcomes, compared to depressed patients.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Pain
  • Depression
Intervention  ICMJE
  • Behavioral: Stepped Care
    Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
  • Drug: Antidepressants
    Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
  • Drug: Usual Care
    This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
    Other Name: Standard Care
Study Arms  ICMJE
  • Experimental: Stepped Care
    Stepped care group
    • Behavioral: Stepped Care
    • Drug: Antidepressants
  • Active Comparator: Usual Care
    Treatment as usual group
    Intervention: Drug: Usual Care
  • No Intervention: No Treatment
    Participants without depression group
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 6, 2005)
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE August 2008
Actual Primary Completion Date July 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Moderate or severe pain in the back, hips, or knees for at least 3 months prior to study entry
  • History of or current use of at least one medication for pain
  • English-speaking

Exclusion Criteria:

  • Moderate to severe cognitive impairment
  • Schizophrenia or other psychotic disorders
  • Receiving disability benefits for pain
  • Anticipated life expectancy less than 12 months
  • Pregnancy
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00118430
Other Study ID Numbers  ICMJE R01MH071268( U.S. NIH Grant/Contract )
R01MH071268 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Data has been published in multiple publications. Should others wish access to data for publication reasons, we are willing to share
Responsible Party Indiana University
Study Sponsor  ICMJE Indiana University
Collaborators  ICMJE National Institute of Mental Health (NIMH)
Investigators  ICMJE
Principal Investigator: Kurt Kroenke, MD Indiana University
PRS Account Indiana University
Verification Date March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP